Vontobel Holding Ltd. Purchases Shares of 325,549 Acelyrin, Inc. (NASDAQ:SLRN)

Vontobel Holding Ltd. acquired a new position in Acelyrin, Inc. (NASDAQ:SLRNFree Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 325,549 shares of the company’s stock, valued at approximately $2,429,000. Vontobel Holding Ltd. owned about 0.33% of Acelyrin as of its most recent filing with the SEC.

Several other hedge funds have also recently made changes to their positions in SLRN. venBio Partners LLC bought a new stake in Acelyrin in the second quarter valued at $80,616,000. FMR LLC boosted its stake in shares of Acelyrin by 20.2% during the 3rd quarter. FMR LLC now owns 8,961,726 shares of the company’s stock valued at $89,914,000 after purchasing an additional 1,505,488 shares in the last quarter. Kynam Capital Management LP purchased a new position in shares of Acelyrin during the third quarter valued at about $12,204,000. Alliancebernstein L.P. bought a new position in Acelyrin in the second quarter worth about $23,894,000. Finally, Woodline Partners LP purchased a new stake in Acelyrin in the second quarter worth about $21,643,000. 87.31% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Acelyrin

In other Acelyrin news, CEO Shao-Lee Lin sold 15,701 shares of Acelyrin stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $7.60, for a total value of $119,327.60. Following the completion of the transaction, the chief executive officer now directly owns 1,587,335 shares of the company’s stock, valued at $12,063,746. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on SLRN shares. HC Wainwright reiterated a “buy” rating and set a $28.00 target price on shares of Acelyrin in a report on Monday, April 1st. Wells Fargo & Company increased their price objective on Acelyrin from $11.00 to $13.00 and gave the stock an “equal weight” rating in a report on Thursday, March 21st. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $23.67.

Read Our Latest Research Report on SLRN

Acelyrin Stock Performance

Acelyrin stock opened at $4.88 on Friday. Acelyrin, Inc. has a twelve month low of $4.76 and a twelve month high of $29.88. The stock’s 50 day moving average is $7.26 and its 200 day moving average is $7.83.

Acelyrin (NASDAQ:SLRNGet Free Report) last released its earnings results on Thursday, March 28th. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.25. On average, research analysts anticipate that Acelyrin, Inc. will post -4.18 EPS for the current year.

Acelyrin Profile

(Free Report)

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.

See Also

Want to see what other hedge funds are holding SLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acelyrin, Inc. (NASDAQ:SLRNFree Report).

Institutional Ownership by Quarter for Acelyrin (NASDAQ:SLRN)

Receive News & Ratings for Acelyrin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acelyrin and related companies with MarketBeat.com's FREE daily email newsletter.